HomeCompareKMED vs EQR

KMED vs EQR: Dividend Comparison 2026

KMED yields 10.63% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $7.4K in total portfolio value· pulled ahead in Year 8
10 years
KMED
KMED
● Live price
10.63%
Share price
$18.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.4K
Annual income
$2,071.13
Full KMED calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — KMED vs EQR

📍 EQR pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKMEDEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KMED + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KMED pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMED
Annual income on $10K today (after 15% tax)
$903.81/yr
After 10yr DRIP, annual income (after tax)
$1,760.46/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $2,893.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMED + EQR for your $10,000?

KMED: 50%EQR: 50%
100% EQR50/50100% KMED
Portfolio after 10yr
$44.1K
Annual income
$3,773.36/yr
Blended yield
8.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

KMED
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMED buys
0
EQR buys
0
No recent congressional trades found for KMED or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKMEDEQR
Forward yield10.63%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$40.4K$47.8K
Annual income after 10y$2,071.13$5,475.61
Total dividends collected$15.6K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KMED vs EQR ($10,000, DRIP)

YearKMED PortfolioKMED Income/yrEQR PortfolioEQR Income/yrGap
1$11,763$1,063.31$11,380$679.82+$383.00KMED
2$13,756$1,168.98$13,014$837.25+$742.00KMED
3$15,996$1,277.54$14,961$1,036.20+$1.0KKMED
4$18,504$1,388.43$17,297$1,289.22+$1.2KKMED
5$21,301$1,501.06$20,121$1,613.15+$1.2KKMED
6$24,407$1,614.86$23,561$2,030.84+$846.00KMED
7$27,844$1,729.28$27,783$2,573.54+$61.00KMED
8← crossover$31,637$1,843.78$33,013$3,284.39$1.4KEQR
9$35,810$1,957.89$39,547$4,223.51$3.7KEQR
10$40,388$2,071.13$47,791$5,475.61$7.4KEQR

KMED vs EQR: Complete Analysis 2026

KMEDStock

The fund will invest at least 80% of its net assets in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index includes companies that RBICS classifies as engaged in the pharmaceuticals, biotechnology, medical specialties, managed health care, hospital/nursing management, medical/nursing services and services to the health industry businesses. The fund is non-diversified.

Full KMED Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this KMED vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMED vs SCHDKMED vs JEPIKMED vs OKMED vs KOKMED vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.